drugset / Trial / NCT00341328

Efficacy and Safety of Immunomodulator as an Adjunct Therapy in New Pulmonary Tuberculosis(Category I) Patients.

NCT00341328 ↗

Phase 3 Completed 300 enrolled Ministry of Science and Technology, India
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of the study is to evaluate the efficacy and safety of Mycobacterium w in new lung tuberculosis patients. Mycobacterium w is a strain of bacterium which is being used as vaccine and adjunct drug against leprosy. This agent has also been found to be useful in the treatment of lung tuberculosis in limited number of patients. We are conducting this study in category-I patients( As per World Health Organization,Geneva classification of tuberculosis) having lung tuberculosis to see the efficacy and also to see any change in the immunological parameters.

Timeline

Start
2007-03
Primary completion
2011-10
Completion
2012-03

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Mycobacterium w Vaccine 0.1 ml Other

Indications